These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22215155)

  • 1. Researchers still seek clinical benefit in raising levels of good cholesterol.
    Mitka M
    JAMA; 2012 Jan; 307(1):21-2. PubMed ID: 22215155
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
    Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
    JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality.
    Pirillo A; Norata GD; Catapano AL
    Curr Pharm Des; 2013; 19(21):3841-57. PubMed ID: 23286430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional assessment of HDL: Moving beyond static measures for risk assessment.
    Rosenson RS
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):71-5. PubMed ID: 20094763
    [No Abstract]   [Full Text] [Related]  

  • 7. Dissociating HDL cholesterol from cardiovascular risk.
    Hausenloy DJ; Opie L; Yellon DM
    Lancet; 2010 Jul; 376(9738):305-6. PubMed ID: 20655104
    [No Abstract]   [Full Text] [Related]  

  • 8. Appropriate clinical use of statins: a discussion of the evidence, scope, benefits, and risk.
    Perlmutter D; Golomb B; Sinatra S; Campbell AW
    Altern Ther Health Med; 2013; 19 Suppl 1():14-25. PubMed ID: 23981463
    [No Abstract]   [Full Text] [Related]  

  • 9. CETP inhibition shows promise as way to reduce cardiovascular disease risk.
    Mitka M
    JAMA; 2011 Jan; 305(2):136-7. PubMed ID: 21224449
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
    Nicholls SJ; Uno K; Kataoka Y
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1383-90. PubMed ID: 22059787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis.
    Hourcade-Potelleret F; Laporte S; Lehnert V; Delmar P; Benghozi R; Torriani U; Koch R; Mismetti P
    Heart; 2015 Jun; 101(11):847-53. PubMed ID: 25872524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial clouds use of niacin with a statin.
    Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606
    [No Abstract]   [Full Text] [Related]  

  • 13. Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story.
    Meagher EA
    Curr Cardiol Rep; 2004 Nov; 6(6):457-63. PubMed ID: 15485608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-density lipoprotein cholesterol as the Holy Grail.
    Cannon CP
    JAMA; 2011 Nov; 306(19):2153-5. PubMed ID: 22089726
    [No Abstract]   [Full Text] [Related]  

  • 15. Controversies on HDL: should it be a target biomarker in patients with lipid disorders?
    Nicholls SJ; Andrews J; Duong M
    Curr Vasc Pharmacol; 2014; 12(4):649-52. PubMed ID: 23627977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment with hydroxymethylglutaryl coenzyme-A-reductase inhibitors in elderly patients: is it necessary?].
    Alexa ID; Panaghiu L; Ungureanu G
    Rev Med Chir Soc Med Nat Iasi; 2005; 109(4):721-6. PubMed ID: 16610166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should every patient with diabetes receive a statin?
    Dembowski E; Davidson MH
    Pol Arch Med Wewn; 2008; 118(7-8):398-401. PubMed ID: 18714733
    [No Abstract]   [Full Text] [Related]  

  • 19. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].
    Einecke D
    MMW Fortschr Med; 2011 Dec; 153(49-50):17-8. PubMed ID: 22308584
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.